Summary

Plecanatride is a 16-amino-acid synthetic peptide analogue of uroguanylin that activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. It stimulates chloride and fluid secretion, making it a key research subject for gastrointestinal motility disorders. It is a licensed POM in the UK.

Overview

Plecanatride is a 16-amino-acid synthetic peptide analogue of the endogenous hormone uroguanylin. It was designed to activate guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells, stimulating fluid and chloride secretion into the intestinal lumen. Developed by Synergy Pharmaceuticals and approved by the FDA in 2018 for chronic idiopathic constipation (CIC), plecanatride represents an important class of peptide-based gastrointestinal therapeutics.

For research and educational purposes only. Plecanatride is a licensed POM in the UK.

Mechanism of Action

Plecanatride mimics uroguanylin, an endogenous peptide hormone produced by enteroendocrine cells in the small intestine. Its mechanism is well-characterised:

  1. GC-C receptor activation: Plecanatride binds to guanylate cyclase-C receptors on the apical (luminal) surface of intestinal epithelial cells.

  2. cGMP production: Receptor activation stimulates the conversion of GTP to cyclic guanosine monophosphate (cGMP), the key intracellular second messenger.

  3. Fluid secretion: Elevated intracellular cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, causing chloride and bicarbonate secretion into the intestinal lumen. Sodium and water follow passively, increasing luminal fluid.

  4. Visceral pain modulation: cGMP may also inhibit nociceptive pain signalling from visceral afferents, a mechanism that has generated research interest for inflammatory bowel disease (IBD) pain models.

Importantly, plecanatride acts locally in the GI tract with minimal systemic absorption (bioactivity is largely luminal), which reduces systemic side-effect concerns.

Research Summary

Evidence Grade: Strong

Plecanatride has robust clinical evidence:

Chronic Idiopathic Constipation (CIC): Two pivotal phase 3 trials (Minematsu et al., 2018; DeMicco et al., 2017) demonstrated that plecanatride 3 mg daily significantly improved complete spontaneous bowel movements (CSBMs) versus placebo, with response rates of 40-50% (vs ~20-30% for placebo).

Irritable Bowel Syndrome with Constipation (IBS-C): A phase 3 trial by Brenner et al. (2018) showed plecanatride improved stool frequency and IBS-related symptoms in IBS-C patients.

Inflammatory Bowel Disease (preclinical): Preclinical research explores plecanatride's potential anti-inflammatory effects via cGMP-mediated signalling in colitis models, though this remains investigational.

Key Studies

  1. Minematsu N et al. Plecanatride for the treatment of chronic idiopathic constipation. Therapeutic Advances in Gastroenterology. 2018;11:1-10.
  2. DeMicco M et al. Plecanatride in CIC: pooled efficacy analysis. American Journal of Gastroenterology. 2017;112(Suppl 1):S413.
  3. Brenner DM et al. Plecanatride in IBS-C: a randomised phase 3 trial. Gut. 2018;67(Suppl 2):A146.
  4. Hamra AK et al. Guanylate cyclase-C agonists for gastrointestinal disorders. Current Opinion in Pharmacology. 2017;37:99-105.

Commonly Discussed Protocols

All information is for research and educational purposes only. Plecanatride is a licensed POM — no protocols for unsupervised use are provided.

In published clinical literature:

  • Oral tablets: 3 mg once daily (CIC); 6 mg once daily (IBS-C)
  • Research dosing in animal models: Varies by species; colitis models typically use 0.3-3 mg/kg orally
  • In vitro research: 0.1-10 microM for GC-C receptor assays in T84 or Caco-2 cell lines

Stacking

No established research protocols combine plecanatride with other peptides. Its local GI mechanism is distinct from most research peptides.

Storage and Reconstitution

  • Storage: Store at room temperature (20-25 degrees C). Protect from moisture.
  • Reconstitution: Commercial plecanatride is available as oral tablets. For laboratory research, lyophilised peptide should be dissolved in sterile water or PBS at neutral pH.
  • Stability: Store reconstituted research material at -20 degrees C. Plecanatride contains disulphide bonds — avoid reducing conditions.

Blood Work

Plecanatride has minimal systemic absorption, so routine blood monitoring is less critical than for systemically active peptides. However:

  • Electrolytes: Monitor for diarrhoea-associated electrolyte disturbances in clinical/research contexts
  • Renal function: No significant renal effects documented, but monitor in vulnerable populations
  • No specific peptide-related biomarkers are established for monitoring

UK Legal Status

Plecanatride is available as a prescription-only medicine (POM) in the UK under certain circumstances. It is regulated by the MHRA. It may be available via specialist import for patients who have failed standard therapies, though it is not as widely prescribed as in the US. It is not a controlled substance.

Research-grade plecanatride for in vitro or laboratory research may be available from established chemical supply houses with appropriate purity documentation. Any use in humans without a prescription is illegal.

Vetted UK Vendors

As plecanatride is a licensed POM, it is not sold as a research peptide by the vetted vendors listed on Peptide Data. Researchers requiring plecanatride for legitimate laboratory research should source it through established chemical supply houses with HPLC-verified purity documentation.

References

  1. Minematsu N et al. Plecanatride for the treatment of chronic idiopathic constipation. Ther Adv Gastroenterol. 2018;11:1-10.
  2. DeMicco M et al. Plecanatride in CIC: pooled efficacy analysis. Am J Gastroenterol. 2017;112(Suppl 1):S413.
  3. Brenner DM et al. Plecanatride in IBS-C: a randomised phase 3 trial. Gut. 2018;67(Suppl 2):A146.
  4. Hamra AK et al. Guanylate cyclase-C agonists for gastrointestinal disorders. Curr Opin Pharmacol. 2017;37:99-105.
  5. Shailubhai K et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse. Cancer Res. 2000;60(18):5151-5157.

References

  1. Minematsu N et al. Plecanatride for the treatment of chronic idiopathic constipation. Ther Adv Gastroenterol. 2018;11:1-10.
  2. DeMicco M et al. Plecanatride in CIC: pooled efficacy analysis. Am J Gastroenterol. 2017;112(Suppl 1):S413.
  3. Brenner DM et al. Plecanatride in IBS-C: a randomised phase 3 trial. Gut. 2018;67(Suppl 2):A146.
  4. Hamra AK et al. Guanylate cyclase-C agonists for GI disorders. Curr Opin Pharmacol. 2017;37:99-105.
  5. Shailubhai K et al. Uroguanylin suppresses polyp formation in Apc(Min/+) mouse. Cancer Res. 2000;60(18):5151-5157.